Patient advocates are warning that a proposal from the FDA meant to reduce consu...
These popular machines may be wildly inaccurate for people with wider or longer ...
In July, Democratic health leaders from the US House of Representatives proposed...
Daxxify becomes the latest botulinum toxin to make the jump from aesthetics to t...
The funding will extend support to the Institute’s Crick Africa Network for five...
The PDUFA date has been pushed by three months to November to allow for more tim...
Novartis obtains two Phase III drugs, atrasentan and zigakibart, and Chinook is ...
New advancements in cold chain monitoring are poised to revolutionise the pharma...
We discuss why demand for ionizable lipid mixes for delivery and target validati...
ImPact Biotech entered into a partnership with Maastricht University to develop ...
Zetagen Therapeutics raised $9.79m in a Series B funding round to develop treatm...
vTv plans to initiate a Phase III study for cadisegliatin with an FDA-recommende...
In the latest edition of STAT's Health Tech newsletter: pharma budget tightening...
TriSalus is breaking into cancer therapeutics research with its TLR agonist SD-1...
Oxurion has received €1m ($1.09m) in funding from Atlas as part of a subscriptio...
Following the business expansion in 2022, Clinigen announced the divestment of f...
